<DOC>
	<DOCNO>NCT03088514</DOCNO>
	<brief_summary>This study aim determine whether dietary inorganic nitrate ( beetroot juice ) able reduce overall thicken heart ( leave ventricular hypertrophy LVH ) stiffness artery give patient persistently raise blood pressure ( hypertension ) . Half patient receive beetroot juice contain inorganic nitrate half receive beetroot juice inorganic nitrate remove . The volunteer take juice every day 4 month .</brief_summary>
	<brief_title>Investigation Dietary Nitrate Effects Hypertension-induced Target Organ Damage</brief_title>
	<detailed_description>In hypertension persistent raise blood pressure ( BP ) associate endothelial dysfunction , arterial stiffness leave ventricular ( LV ) remodel key phenomenon associate pathogenesis complication hypertension . One main substance healthy endothelium produce responsible maintain patency blood vessel nitric oxide ( NO ) . In hypertension , one key pathogenic effect dysfunction endothelium characterize decrease ability generate nitric oxide ( NO ) . Previous study show dietary inorganic nitrate supplementation lower blood pressure ( Kapil et al . 2015 ) , however , whether approach might also improve endothelial function LV remodel unknown . The effect inorganic nitrate due conversion body inorganic nitrite thereafter NO . This study assess effect dietary inorganic nitrate LVH use cardiac magnetic resonance imaging ( NITRATE-LVH arm ) . In addition , effect dietary inorganic nitrate central aortic blood pressure , arterial stiffness use pulse wave velocity endothelial function use flow mediate dilatation evaluate ( NITRATE-CBP arm ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . Patients enrol follow informed consent . The subject able understand comply protocol requirement , instruction protocol restriction . 2 . The study subject hypertensives evidence difficulty treat target BP ( daytime ABPM 135170/85105 mmHg ) 13 antihypertensive agent , insufficient efficacy intolerance medication . 3 . For NITRATE LVH , echocardiographic evidence LV hypertrophy ( LV mass indexed body surface area ( BSA ) ; male &gt; 115g/m2 ; female &gt; 95 g/m2 ) . 4 . Patients establish antihypertensive treatment regime least 1 month time participation study require change pharmacological intervention duration trial . 1 . History chronic viral hepatitis ( include presence hepatitis B surface antigen hepatitis C antibody ) , chronic hepatic disorder . 2 . History increase liver function test ( ALT , AST ) due acute chronic liver condition , 3x upper limit normal bilirubin 1.5x upper limit normal screening . 3 . Renal impairment creatinine clearance ( eGFR ) &lt; 50 ml/min screening . 4 . Patients diabetes mellitus , define previous history diabetes HbA1c &gt; 6.5 % ( &gt; 48 mmol/mol ) screening . 5 . Subjects LDLc , &gt; 7.5 mmol/l . Triglycerides level &gt; 10mmol/l . 6 . History heart failure define NYHA class II ‐ IV know leave ventricular dysfunction ( ejection fraction &lt; 40 % ) regardless symptomatic status 7 . History malignancy within past 5 year , nonmelanoma skin cancer . 8 . Current lifethreatening condition vascular disease ( e.g . severe chronic airway disease , HIV positive , life‐threatening arrhythmia ) may prevent subject complete study . 9 . Use investigational device investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . 10 . Subjects commence likely commence treatment nonsteroidal antiinflammatory drug ( NSAIDs ) ( aspirin ) , screen study completion . 11 . Any nonstable dosing ongoing medication regimen throughout study trial . 12 . Alcohol drug abuse within past 6 month . 13 . The subject threemonth prior history regular alcohol consumption exceed average weekly intake &gt; 28 unit ( average daily intake great 3 unit ) male , average weekly intake &gt; 21 unit ( average daily intake great 2 unit ) female . 1 unit equivalent halfpint ( 284mL ) beer/lager ; 25mL measure spirit 125mL wine . 14 . Any subject Investigator deems unsuitable study ( e.g . due medical reason , laboratory abnormality , expect study medication noncompliance , subject 's unwillingness comply studyrelated study procedure ) . 15 . Subjects rheumatoid arthritis , connective tissue disorder condition know associate chronic inflammation ( e.g . Inflammatory Bowel Disease ) . 16 . Subjects acute infection , recent systemic ( oral iv ) antibiotic within 3 month screen , significant trauma ( burn , fracture ) . 17 . Subjects donate 500 mL blood within 56 day prior study medication administration . 18 . Self report use antimicrobial mouthwash tongue scrape . 19 . Concomitant xanthine oxidase inhibitor ( allopurinol ) . 20 . Known history significant claustrophobia , previous intolerance CMR image know ( suspect ) incompatible metallic implant . 21 . Pregnancy 22 . Allergy gadoliniumbased contrast agent use CMR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Left Ventricular Hypertrophy</keyword>
	<keyword>Endothelial Dysfunction</keyword>
	<keyword>Nitrate</keyword>
</DOC>